AstraZeneca, which pledged to provide its COVID-19 vaccine at no profit for the duration of the pandemic, said Thursday that losses in the first half of the year on its vaccine shaved 4 cents off the pharmaceutical giant’s earnings per share.
Sales of Vaxzevria, the company’s COVID-19 vaccine, generated $1.17 billion in revenue during the first six months of the year, including $894 million in the second quarter, according to AstraZeneca’s earnings report, released on July 29.
